GlassScriptPhysician profile
Andrea C Johnson
NPI 1528221520
$1,041.87
in general payments reported to CMS, 2019-2025
24 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $258 · 2023: $147 · 2024: $144 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.32 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $75.96 | 2021 | |
| Lilly USA, LLC | $72.36 | 2021-2022 | |
| Novo Nordisk INC | $67.17 | 2021-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.87 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $52.47 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.85 | 2025 | Caplyta |
| Pfizer INC. | $43.16 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $31.21 | 2022 | |
| Gilead Sciences, INC. | $30.14 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.04 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $27.79 | 2021-2025 | Fasenra |
| Genentech USA, INC. | $19.10 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.00 | 2024 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.22 | 2024 | Veozah |
| Organon LLC | $17.15 | 2022 | |
| Dexcom, INC. | $16.91 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $15.00 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2023 | Seglentis, Livalo |
| Biogen, INC. | $12.63 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.